BRAF and ovarian carcinoma: Consistent with the bimolecular significance of BRAF protein and its V600E mutation in carcinogenesis, several drugs targeting BRAF V600E mutations have been approved or under development to treat melanoma, ovarian cancer, thyroid cancer and colorectal cancer [28].